Indivior continues legal struggles over Suboxone exclusivity
The US business of London-listed Indivior (LON: INDV) says it has filed patent infringement lawsuits against Dr Reddy's Laboratories (BSE: 500124), Actavis, Par Pharmaceutical, Alvogen and Teva Pharmaceutical Industries (NYSE: TEVA) relating to their respective proposed generic versions of Suboxone (buprenorphine and naloxone).
Indivior says the firms are violating its '305 patent, which was issued on April 3.
Indivior has been engaged in extensive patent tussles related to the opioid addiction treatment. One adverse ruling in a US District Court last year impacted the firm’s share price considerably, as did a ruling in favor of generic rival Alvogen last month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze